Szemészet, 2016 (153. évfolyam, 1-4. szám)
2016-12-01 / 4. szám
Mineralocorticoid antagonist therapy 4. Central Serous Chorioretinopathy and Bouzas EA, Karadimas R Pournaras CJ. Glucocorticoids Surv Ophthalmol 2002; 47: 431-448. 5. Carvalho-Recchia CA, Yannuzzi LA, Negräo S, Spaide RE Freund KB, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology 2002; 109: 1834-1837. B. Danjuma, Mukherjee, Makaronidis, Osula: Converging Indications of Aldosterone Antagonists (Spironolactone and Eplerenone): A Narrative Review of Safety Profiles. Curr Hypertens Rep 2014; 1B: 414. 7. Fine HE Ober MD, Hariprasad SM. Current concepts in managing central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging Retina 2014; 45: 9-13. 8. Ghadiali Q, Jung JJ, Yu S, et al. Central serous chorioretinopathy treated with mineralocorticoid antagonists: a one-year pilot study. Retina 2016; 36: 611-618. 9. Golestaneh N, Picaud S, Mirshahi M. The mineralocorticoid receptor in rodent retina: ontogeny and molecular identity. Mol Vis 2002; 8: 221-225. 10. Gruszka A. Potential involvement of mineralocorticoid receptor activation in the pathogenesis of central serous chorioretinopathy: case report. European Review for Medical and Pharmacological Sciences 2013; 17: 1369-1373. 11. Hamzah E Shinojima A, Mori R, Yuzawa M. Choroidal thickness measurement by enhanced depth imaging and swept-source optical coherence tomography in central serous chorioretinopathy. BMC Ophthalmol 2014; 25(14): 145. 12. Haimovici R, Koh S, Gagnon Dr, Lehrfeld T, Wellik S. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 2004; 111: 244-249. 13. Herold TR, Prause К, Wolf A, et al. Spironolactone in the treatment of central serous chorioretinopathy - a case series. Graefes Arch Clin Exp Ophthalmol 2014; 252: 1985-1991. 14. Imamura Y, Fujiwara T, Margolis R, Spaide RE Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2009; 29: 1469-1473. 15. Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology 2008; 115: 169-73. 16. Li XJ, Zhang JS. Intravitreal bevacizumab injection for chronic central serous chorioretinopathy. Chin Med J (Engl) 2010; 123: 2145-2147. 17. Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clinical and Experimental Ophthalmology 2013; 41: 201-214. 18. Lim JW, Kang SW, Kim YT, Chung SE, Lee SW. Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy. Br J Ophthalmol 2011; 95: 514-517. 19. Lim JW, Kim MU. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2011; 249: 969-974. 20. Lim JW, Ryu SJ, Shin MC. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J Ophthalmol 2010; 24: 155-158. 21. Lim SJ, Roh Ml, Kwon OW. Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina 2010; 30: 100-106. 22. Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye 2010; 24: 1743-1756. 23. Maruko I, lida T, Sugano Y, Ojima A, Sekiryu T. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. Retina 2011; 31: 1603-1608. 24. Mccurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol 2012; 350: 256-265. 25. Nicholson B, Noble J, Forooghian E Meyerle C. Central Serous Chorioretinopathy: Update on Pathophysiology and Treatment. Surv Ophthalmol 2013; 58: 103-126. 26. Odermatt A, Kratschmar DV. Tissue-specific modulation of mineralocorticoid receptor function by 11 B-hydroxysteroid dehydrogenases: an overview. Mol Cell Endocrinol 2012; 350: 168-186. 27. Pryds A, Sander B, Larsen M. Characterization of subretinal fluid leakage in central serous chorioretinopathy. Invest Ophthalmol Vis Sei 2010; 51: 5853-5857. 28. Quin G, Liew G, Ho Iv, Gillies M, Fraser-Bell S. Diagnosis and interventions for central serous chorioretinopathy: review and update. Clinical and Experimental Ophthalmology 2013; 41: 187-200. 29. Ross A, Ross AH, Mohamed Q. Review and update of central serous chorioretinopathy. Curr Opin Ophthalmol 2011; 22: 166-73. 30. Spaide RE Campeas L, Haas A, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology 1996; 103: 2070-2079. 31. White PC, Mune T, Agarwal AK. 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 1997; 18: 135-156. 32. Wilkinson-Berka JL, Tan G, Jaworski K, Miller AG. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res 2009; 104: 124-133. 33. Wu ZH, Lai RY, Yip YW, Chan WM, Lam DS, Lai TY. Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial. Retina 2011; 31: 1378-1386. 34. Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003; 23: 288-298. 35. Zakir SM, Shukla M, Simi ZU, Ahmad J, Sajid M. Serum cortisol and testosterone levels in idiopathic central serous chorioretinopathy. Indian J Ophthalmol 2009; 57: 419-422. 36. Zhao M, Célérier I, Bousquet E, Jeanny JC, Jonet L, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 2012; 122: 2672-2679. 37. Zhao M, Valamanesh E Celerier I, Savoldelli M, Jonet L, et al. The neuroretina is a novel mineralocorticoid target: aldosterone upregulates ion and water channels in Müller glial cells. Faseb J 2010; 24: 3405-3415. Levelezési cím Dr Gergely Róbert, 1085 Budapest, Mária utca 39. E-mail: gergelyrobert.dr@gmail.com \ ^ ^ ✓
